Interventions such as left ventricular assist device (LVAD) unloading, HDAC inhibitors, SGLT2 inhibitors, and direct fibroblast reprogramming have been shown to partially reverse fibrosis and structural-functional abnormalities, highlighting its potential as a therapeutic target in HF (75, 86–88). This evidence concerns the gene SLC5A2 and hydrops fetalis.